We are live on ! Find out more
AMPH icon

Amphastar Pharmaceuticals

271 hedge funds and large institutions have $1.47B invested in Amphastar Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 89 increasing their positions, 98 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more call options, than puts

Call options by funds: $3.17M | Put options by funds: $2.61M

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

0.92% less ownership

Funds ownership: 70.69%69.78% (-0.92%)

9% less repeat investments, than reductions

Existing positions increased: 89 | Existing positions reduced: 98

2% less funds holding

Funds holding: 277271 (-6)

11% less first-time investments, than exits

New positions opened: 47 | Existing positions closed: 53

30% less capital invested

Capital invested by funds: $2.09B → $1.47B (-$622M)

Holders
271
Holders Change
-6
Holders Change %
-2.17%
% of All Funds
3.9%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
47
Increased
89
Reduced
98
Closed
53
Calls
$3.17M
Puts
$2.61M
Net Calls
+$553K
Net Calls Change
-$610K
Name Holding Trade Value Shares
Change
Change in
Stake
CA
251
Crewe Advisors
Utah
$3.12K
LC
252
Lindbrook Capital
California
$2.77K -$1.65K -32 -34%
Ohio Public Employees Retirement System (OPERS)
253
Ohio Public Employees Retirement System (OPERS)
Ohio
$2.42K +$2.84K +55 New
RA
254
Rise Advisors
New York
$2.2K +$2.58K +50 New
GRP
255
Global Retirement Partners
California
$2.06K -$2.53K -49 -51%
PWMG
256
Private Wealth Management Group
New Jersey
$1.76K
CWC
257
Carolinas Wealth Consulting
North Carolina
$1.44K
FMII
258
Farmers & Merchants Investments Inc
Nebraska
$1.23K
PA
259
Parallel Advisors
California
$878 -$3.87K -75 -79%
UB
260
UMB Bank
Missouri
$703 +$826 +16 New
BIA
261
Bell Investment Advisors
California
$659
FSWA
262
Financial Synergies Wealth Advisors
Texas
$659
Kayne Anderson Rudnick Investment Management
263
Kayne Anderson Rudnick Investment Management
California
$659 +$775 +15 New
JWA
264
JFS Wealth Advisors
Pennsylvania
$484 -$52 -1 -8%
AWM
265
Avior Wealth Management
Nebraska
$307 -$3.77K -73 -91%
ECM
266
Everence Capital Management
Indiana
$284
AWM
267
Abound Wealth Management
Tennessee
$264 +$310 +6 New
RIL
268
Rothschild Investment LLC
Illinois
$220 +$258 +5 New
SIC
269
SJS Investment Consulting
Ohio
$88 -$155 -3 -60%
A
270
AlphaQuest
New York
$44 +$52 +1 New
FGAM
271
Financial Gravity Asset Management
Texas
$41
BHWA
272
Beacon Harbor Wealth Advisors
Virginia
-$6.38M -103,140 Closed
D.E. Shaw & Co
273
D.E. Shaw & Co
New York
-$4.77M -77,080 Closed
PCM
274
Penserra Capital Management
California
-$3.02M -48,749 Closed
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
275
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
-$2.78M -45,000 Closed

AMPH Hedge Fund Activity: Q1 2024 in Review

271 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q1 2024, worth a combined $1.47B — down 30% from $2.09B a quarter earlier.

Sellers outnumbered buyers: 53 funds closed out of AMPH and 47 opened new positions — a net loss of 6 holders — while 98 trimmed existing stakes and 89 added.

The largest buyer was American Century Companies, adding an estimated $14.5M. The largest seller was Federated Hermes, cutting an estimated $61.8M.

  • 271 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q1 2024, down from 277 in Q4 2023.
  • Funds reported $1.47B of Amphastar Pharmaceuticals stock for Q1 2024, down 30% quarter-over-quarter.
  • 47 funds opened new Amphastar Pharmaceuticals positions in Q1 2024 and 53 closed out, a net change of -6 holders.
  • The largest Amphastar Pharmaceuticals buyer in Q1 2024 was American Century Companies, an estimated $14.5M added.
  • The largest Amphastar Pharmaceuticals seller in Q1 2024 was Federated Hermes, an estimated $61.8M sold.

Based on aggregated 13F filings for Q1 2024.